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Introduction
Opioid receptor antagonists have been used in the treatment of opioid addiction and overdose (Gonzalez et al., 2004) . In addition, opioid antagonists, such as naltrexone, can be used to treat alcoholism and pruritus associated with liver diseases or opioid medications (Anton, 2001; Jones et al., 2002) . Although opioid antagonists have wide therapeutic applications, withdrawal symptoms elicited by these antagonists have limited their pharmacotherapy in opioid-treated or -dependent subjects (O'Connor and Kosten, 1998; Gonzalez et al., 2004) . Research and development of compounds that produce therapeutic effects but elicit reduced withdrawal symptoms have become important in the pharmacotherapy of opioid antagonists.
6β-Naltrexol is the major metabolite of naltrexone in humans, but not in rodents (Misra et al., 1976; Meyer et al., 1984) . The plasma level of 6β-naltrexol is approximately 2-to 3-fold higher than that of naltrexone in humans (Meyer et al., 1984; Ferrari et al., 1998) . However, there is no information on the characteristics of 6β-naltrexol in vivo in primates. More importantly, recent studies have found that pharmacological actions of 6β-naltrexol are different from those of naltrexone, and antagonist doses of 6β-naltrexol elicit less behavioral withdrawal signs in morphinedependent mice (Wang et al., 2004; Raehal et al., 2005) . These findings appear to indicate that 6β-naltrexol is a putative neutral antagonist in mice and it may have greater therapeutic potential in treating opioid addiction and overdose (Raehal et al., 2005) .
Therefore, it is of interest to study the pharmacological actions of 6β-naltrexol in a primate species. Although early studies of opioid dependence in monkeys relied on subjective observation of behaviors, monkeys during morphine withdrawal display several physiological responses closely resembling those in humans (Seevers, 1936; Holtzman and Villarreal, 1969; Heishman et al., 1989) . For example, both morphine abstinence and antagonist administration have been reported to produce hyperpnea in morphinedependent human subjects (Martin et al., 1968; Heishman et al., 1989) . Increased respiratory frequency can be detected and be used as a sensitive, quantitative measure of precipitated opioid withdrawal in acute and chronic morphine-dependent monkeys (Paronis and Woods, 1997; Kishioka et al., 2000) . Opioid antagonists have similar in vivo potency in precipitating withdrawal across different monkey behavioral assays (Valentino et al., 1983; France and Woods, 1989; Paronis and Woods, 1997) . More importantly, opioid antagonists such as naltrexone retain the same potency in both producing µ-opioid receptor (MOR) antagonist effects and precipitating withdrawal in monkeys (France et al., 1990; Ko et al., 1998) . These findings suggest that binding to opioid receptors is the mechanism by which antagonists precipitate withdrawal in opioiddependent subjects (France et al., 1990) . It is valuable to compare the potency of 6β-naltrexol under both experimental conditions in monkeys.
The aim of this study was therefore to characterize the pharmacological actions of 6β-naltrexol in a primate species. In the current study, the MOR binding affinities of both naltrexone and 6β-naltrexol were determined in the cortical and thalamic membranes of monkeys. In vitro antagonist potencies of both compounds were compared using a MOR agonist-induced [ (Ko et al., 2003) . Apparent pA 2 analysis was used to determine the in vivo antagonist potency of 6β-naltrexol and to be compared with the pA 2 value of naltrexone under similar conditions (Ko et al., 1998) . Antagonist effects of 6β-naltrexol were also compared with naltrexone in different MOR-mediated behavioral endpoints including itch/scratching and respiratory depression (Ko et al., 2002 (Ko et al., , 2004 . Furthermore, in vivo potencies of naltrexone and 6β-naltrexol in precipitating withdrawal were compared by measuring respiratory parameters in morphine-dependent monkeys (Paronis and Woods, 1997; Kishioka et al., 2000) .
This article has not been copyedited and formatted. The final version may differ from this version. 
Methods
Subjects
Eighteen adult intact male and female rhesus monkeys (Macaca mulatta) with body weights ranging between 6.8 and 11.8 kg were used. They were housed individually with free access to water and were fed approximately 25 to 30 biscuits (Purina Monkey Chow; Ralston Purina, St. Louis, MO) and fresh fruit daily. No monkey had exposure to opioids for one month before the present study. The monkeys were housed in facilities accredited by the American Association for the Accreditation of Laboratory Animal Care.
The studies were conducted in accordance with the University Committee on the Use and Care of Animals in the University of Michigan and the Guide for the Care and Use of Laboratory Animals (National Academy Press, Washington DC, revised 1996).
Procedures
I. In Vitro Binding Assays
Ligand Binding Assay.
Both cortical and thalamic membranes of monkeys were prepared according to the procedure described in a previous study (Ko et al., 2003) . Cortical membranes (400 µg Samples were rapidly filtered through glass fiber filters (no. 32, Schleicher and Schuell, Keene, NH) mounted in a Brandell cell harvester (Gaithersburg, MD) and rinsed three times with Tris-HCl buffer. Filters were placed in 5 mL polypropylene scintillation vials, and radioactivity retained on the filters was measured by liquid scintillation counting in 4 mL EcoLume. Each experiment was carried out three times in duplicate. mounted in a Brandell harvester and rinsing three times with 50 mM Tris, pH 7.4, 5 mM MgCl 2 , and 100 mM NaCl. Filtermats were dried, and 0.1 mL EcoLume was added to each sample. Filtermats were heat sealed in polyethylene bags, and radioactivity retained on the filters was measured by liquid scintillation counting in Wallac 1450
MicroBeta Liquid Scintillation and Luminescence Counter (Perkin Elmer, Boston, MA).
Each experiment was carried out three times in duplicate.
Data Analysis.
IC 50 values were determined using Graphpad Prism Version 4.0 (Graphpad, San Diego, CA) and converted to K i values according to Cheng and Prusoff (1973 C. Tailwithdrawal latencies were measured using a computerized timer by an experimenter who was blinded to experimental conditions. In each test session, monkeys were tested one to two times at three temperatures in a random order. If the monkeys did not remove their tails within 20 sec (cutoff), the flask was removed and a maximum time of 20 sec was recorded. Test sessions began with control determinations at each temperature. Then, a MOR-selective agonist, alfentanil, was administered by either a cumulative or single dosing procedure. Subsequent tail-withdrawal latencies were determined starting 15 min after each injection.
Respiratory Function.
The monkey was seated in a primate restraint chair, enclosed within a soundattenuating chamber. A rectangular helmet (13.5 x 17.0 x 13.5 cm) was placed over the head of the monkey and sealed around its neck by two closely fitting latex shields. Gas (either air or a mixture of 5% CO 2 in air) flowed into the helmet and was pumped out at a rate of 8 liters/min. The monkeys' breathing produced changes in pressure inside the helmet that were measured with a pressure transducer connected to a polygraph (Grass Model 7); the data were recorded on a polygraph trace and in a microprocessor (IBM PC) via an analog-to-digital converter. The apparatus was calibrated routinely with known quantities of air. The polygraph integrator was connected to a computer, which analyzes the data collected over a 3-min period. The rate of breathing (f, respiratory frequency) is determined directly. The minute volume (V E ) is determined from the integration of the plethysmograph system. When the test compound was given in a cumulative dosing procedure, the test session contained 6 consecutive cycles. Each cycle was 30 min, which included the first 23 min exposure to air alone and remaining 7 min exposure to 5% CO 2 mixed in air. Responses in the first 2 cycles were averaged as a baseline (control) value. Naltrexone, 6β-naltrexol, or vehicle solution was administered intramuscularly in the beginning of each cycle for the remaining dosing-injection cycles (i.e., from 3 rd to 6 th cycle). The doses were increased by a 0.5 log unit throughout the test sessions. Each experimental condition was repeated at least once in all subjects.
Scratching Responses.
Scratching responses, inferred as an itch sensation, were recorded on videotapes when monkeys were in their home cages. Each recording session was conducted for 15 min/test session (i.e., 16 th -30 th min after alfentanil administration). A scratch was defined as one short-duration (< 1sec) episode of scraping contact of the forepaw or hind paw on the skin surface of other body parts. Scratches usually occurred repetitively 
Experimental Designs a. µ-opioid receptor antagonist potencies of naltrexone and 6β-naltrexol
A previous study has reported an in vivo apparent pA 2 value of naltrexone against alfentanil-induced antinociception (Ko et al., 1998) . For comparison, we used the same experimental conditions to determine the antagonist potency of 6β-naltrexol in non-dependent (i.e., morphine-untreated) monkeys. Multiple doses of 6β-naltrexol (0, 0.1, 0.32, 1, 3.2 mg/kg, s.c.) were tested by using a single dosing procedure. The doseresponse curve of s.c. alfentanil-induced antinociception was re-determined 30 min after pretreatment with 6β-naltrexol. Experiments were conducted once per week.
The second part of the antagonist study was to compare the potency of i.v.
naltrexone and 6β-naltrexol against MOR-mediated behavioral effects. Although MOR agonists produce antinociception, respiratory depression, and itch/scratching mainly through central MOR activation in monkeys (Ko et al., 2002 (Ko et al., , 2004 
b. Naltrexone-and 6β-naltrexol-precipitated withdrawal
Previous studies have shown that naltrexone precipitated withdrawal measured by increased f and V E in acute and chronic morphine-dependent monkeys (Paronis and Woods, 1997; Kishioka et al., 2000) . Therefore, we used the respiratory parameters to quantify the degree of acute dependence and to compare the potency of naltrexone and 6β-naltrexol in precipitating withdrawal. Our pilot study indicated that following 3 days of morphine treatment (6.4 mg/kg/day, i.m.), naltrexone consistently produced a 2-fold increased f and V E of the baseline value when monkeys were exposed to air or 5% CO 2 mixed in air. We further used this dosing regimen which acutely produced a minimum, but significant degree of opioid dependence to compare the dose response curves of both compounds. Monkeys received two i.m. injections of 3.2 mg/kg of morphine (i.e., at 9:00 A.M. and 3:00 P.M.) daily for 3 days. On the fourth day, effects of naltrexone (0.001-0.032 mg/kg, i.m.) or 6β-naltrexol (0.1-3.2 mg/kg, i.m.) were determined at 9:00 A.M. by using a cumulative dosing procedure. Effects of vehicle (0.1 mL/kg, i.m.) were also studied under the same procedure (i.e., 4 dosing-injection cycles) in acute morphine-dependent monkeys. In addition, effects of naltrexone and 6β-naltrexol alone were tested in morphine-untreated monkeys. Experiments were normally conducted once per 2-3 weeks in order to assure that this acute morphine dependence had dissipated because our pilot studies and previous studies have shown that dependence dissipated over the course of 5-7 days following cessation of acute or chronic morphine administration (Paronis and Woods, 1997; Kishioka et al., 2000) .
c. Effect of 6β-naltrexol on naltrexone-precipitated withdrawal
The third part of the behavioral study was to investigate whether 6β-naltrexol can act as a neutral antagonist by determining if it can block naltrexone-precipitated withdrawal in acute morphine-dependent monkeys. Using the same dosing regimen for developing acute morphine dependence, effects of small doses of 6β-naltrexol that produced no or mild increments in f and V E on the dose-response curve of naltrexoneprecipitated withdrawal were studied. Either vehicle (0.1 mL/kg) or 6β-naltrexol (0.1-0.32 mg/kg) was administered intramuscularly (i.e., at the beginning of the 3 rd cycle) 30 min before administration of naltrexone cumulative dosing in the remaining cycles (i.e., from 4 th to 6 th cycle). Similarly, experiments were conducted once per 2-3 weeks in order to assure that acute morphine dependence had dissipated before starting of next experiment. 6β-naltrexol and naltrexone were able to dose dependently displace the binding of homogenates of monkey thalamus which expresses predominantly µ-opioid receptors (Ko et al., 2003) . Experiments were performed in low ionic strength 50 mM Tris buffer, pH 7.4 or in 50 mM Tris containing 100 mM NaCl, and 10 µM GTPγS to promote a low agonist affinity state of the receptor. Naltrexone had a higher affinity (K i = 1.7 ± 0.3 nM) than 6β-naltrexol (K i = 3.2 ± 0.3 nM) for displacing [ µM). The K e value, the antagonist equilibrium affinity constant, for the degree of antagonist-induced shift is 1.17 ± 0.08 nM for 6β-naltrexol and 0.52 ± 0.09 for naltrexone (p<0.05), suggesting that naltrexone has two-fold higher affinity than 6β-naltrexol for the µ-opioid receptor. 
Drugs
II. Behavioral Assays a. µ-opioid receptor antagonist potencies of naltrexone and 6β-naltrexol
b. Naltrexone-and 6β-naltrexol-precipitated withdrawal
The potency difference between naltrexone and 6β-naltrexol in precipitating withdrawal was compared in acute morphine-dependent monkeys ( Figure 6 ). Both naltrexone-and 6β-naltrexol-induced increments in f and V E were similar in a dosedependent manner whether dependent-monkeys were breathing air or air mixed with 5% CO 2 . For the sake of the simplicity of data presentation, only data during exposure to air are presented (Ko et al., 2002) . powerful approach for establishing receptor-mediated drug effects (Arunlakshana and Schild, 1959; Tallarida et al., 1979; Ward and Takemori, 1983) . In the present study, 6β-naltrexol dose-dependently produced parallel rightward shifts of the dose-response curve of alfentanil-induced antinociception (Figure 4) , indicating that the agonist and antagonist compete for the same receptor site in a reversible manner (Arunlakshana and Schild, 1959; Tallarida et al., 1979) . The pA 2 value of 6β-naltrexol, 6.5, which was approximately 100-fold less than the naltrexone pA 2 value of 8.5 determined under the same behavioral assay conditions (Ko et al., 1998) . It is expected that the pA 2 values of the same antagonist are similar across different behavioral measures for effects mediated by a common receptor population (Ward and Takemori, 1983; Negus et al., 1993) . Consequently, the in vivo antagonist potencies of naltrexone and 6β-naltrexol were further compared by using another administration route and other behavioral endpoints demonstrated to be mediated by central MOR (Ko et al., 2002 (Ko et al., , 2004 . Again, i.v. 6β-naltrexol was much less potent than naltrexone, and 1 mg/kg of 6β-naltrexol produced comparable blockade of alfentanil-induced antinociception, itch/scratching, and respiratory depression as 0.01 mg/kg of naltrexone ( Figure 5 ). These results appear to indicate that both naltrexone and 6β-naltrexol produce MOR antagonist effects in vivo, but with a consistent, large potency difference across different behavioral assays.
The in vitro binding assays may not be able to predict the in vivo apparent affinity for antagonists. For example, an opioid receptor antagonist, quadazocine, displayed 4-fold higher affinity than naltrexone for sites labeled by [ JPET #94409 21 7.9) were 10-fold less potent than those of naltrexone (8.5-8.8) across different MORmediated behavioral endpoints (France et al., 1990; Negus et al., 1993; Ko et al., 1998) .
It is possible that 6β-naltrexol does not enter the brain as readily as naltrexone or that 6β-naltrexol is a better substrate than naltrexone for P-glycoprotein pumps removing ligands from the brain. Future studies measuring the concentrations of naltrexone and 6β-naltrexol in the monkey brain will be important to verify whether a large in vivo potency difference between ligands is due to the difference in the concentrations achieved in the vicinity of MOR receptors mediating the measured responses.
Regardless, a large difference of in vivo potency between naltrexone and 6β-naltrexol has also been reported in rodent studies. 6β-Naltrexol was approximately 85-fold and 180-fold less potent than naltrexone in antagonizing MOR-mediated Straub tail and antinociception in mice, respectively Porter et al., 2002) . In contrast, other studies showed that 6β-naltrexol was only 3-10 fold less potent than naltrexone in antagonizing morphine-induced antinociception and locomotor activity in mice (Wang et al., 2001; Raehal et al., 2005) . Unfortunately, these mouse studies did not use the in vivo apparent pA 2 analysis to systematically quantify and compare the antagonist potency of naltrexone and 6β-naltrexol across different behavioral endpoints.
In vivo potencies of naltrexone and 6β-naltrexol were further compared in acute morphine-dependent monkeys. In the present study, both antagonists dose dependently precipitated withdrawal manifested by increased respiratory parameters (i.e., f and V E in Figure 6 ). 6β-Naltrexol was approximately 80-to 95-fold less potent than naltrexone in precipitating withdrawal in morphine-treated monkeys. Both naltrexone and 6β-naltrexol at doses producing MOR antagonist effects also precipitated withdrawal in morphine- (France et al., 1990; Ko et al., 1998) and precipitating withdrawal (Valentino et al., 1983; France and Woods, 1989; France et al., 1990; Paronis and Woods, 1997) measured by different behavioral assays. More importantly, these findings are consistent with human studies showing that the doses of naloxone or naltrexone effective in blocking the effects of MOR agonists can also precipitate withdrawal in acute or chronic opioid-dependent subjects (Stitzer et al., 1991; Eissenberg et al., 1996; Walsh et al., 1996) .
A recent study has shown that 6β-naltrexol may act as a neutral antagonist, while naltrexone displays an inverse agonist action, in acute morphine-dependent mice (Raehal et al., 2005) . If a compound is a neutral antagonist, it is expected that this compound should block both agonist and inverse agonist actions (Kenakin, 2001 ).
However, 6β-naltrexol failed to block naltrexone-precipitated withdrawal in acute morphine-dependent monkeys; instead, it potentiated the effects of naltrexone when the dose of 6β-naltrexol was increased (Figure 7 ). There might be differences between primates and rodents in terms of the MOR basal signaling activity changed by MOR agonist administration. Naltrexone, but not 6β-naltrexol, slightly decreased [
S]GTPγS
binding (i.e., 5-10 % reduction from the basal level) in brain homogenates from morphine-treated mice (Wang et al., 2004) . However, 6β-naltrexol at high doses can precipitate withdrawal in morphine-treated mice (Raehal et al., 2005) . It will be valuable to explore whether a robust measure of inverse agonist action can be established in the morphine-treated monkey brain homogenates and to determine whether withdrawal Withdrawal syndromes resulting from chronic dependence tend to be more intense and of longer duration than that from acute dependence; however, the observed signs and symptoms are qualitatively similar. The morphine dosing regimen used in this study produced a minimum, but significant degree of physiological dependence on morphine to allow quantitative comparison of the potency of naltrexone and 6β-naltrexol. It is worth noting that precipitated withdrawal was measured at 18 hours after the last injection of morphine, at which time point the amount of morphine was relatively low (Domino et al., 1987) . Most withdrawal signs can be observed between 8 and 48 hours postmorphine in both precipitated and abstinence-associated withdrawal in monkeys (Domino et al., 1987; France and Woods, 1989; Paronis and Woods, 1997; Kishioka et al., 2000) . For comparison, 6β-naltrexol and naltrexone can precipitate withdrawal to a similar degree in mice implanted with morphine pellets, but they do not appear to do so when the degree of dependence is less severe (Fujimoto et al., 1975; Raehal et al., 2005) . The only discrepancy among mouse studies is the difference of the MOR antagonist potency between naltrexone and 6β-naltrexol (i.e., 85-180 fold vs. 3-10 fold) Wang et al., 2001; Porter et al., 2002; Raehal et al., 2005 In summary, this study demonstrates that naltrexone and 6β-naltrexol display similar pharmacological actions with different in vivo potencies in monkeys. Naltrexone is slightly potent than 6β-naltrexol (i.e., 2-fold) in producing antagonist effects in vitro measured in the monkey brain membranes. However, naltrexone is much more potent than 6β-naltrexol (i.e., 100-fold) in producing in vivo MOR antagonist effects. More importantly, both antagonists retain the same relative potency in precipitating withdrawal in acute morphine-dependent monkeys. 6β-Naltrexol might not be a neutral antagonist since it failed to block the actions of naltrexone-precipitated withdrawal under these experimental conditions. Although 6β-naltrexol is 2-3 fold higher than naltrexone in the plasma level in humans (Meyer et al., 1984; Ferrari et al., 1998) , 6β-naltrexol may play a minimal role in the therapeutic or antagonist effects of naltrexone in primates. 
